Seems like a lot to ask given our current SP levels and the likelihood that such a move would necessitate an uplist and institutions buying. I hope you are right, but at this point I would be surprised if we were to rise much over $1. With the addition of solid Prurisol trial results and another partnership/asset sale I think we could get there, but otherwise we may still need a RS in order to uplist IMO.